Efficacy of Bifidobacterium infantis 35624 in patients with irritable bowel syndrome: a meta-analysis

Current Medical Research and Opinion

Volumn 33, Issue 7, 2017, Pages 1191-1197

  Yuan, Fuqiang ^a   Ni, Huijuan ^b   Asche, Carl V ^c,d   Kim, Minchul ^c   Walayat, Saqib ^e   Ren, Jinma ^c  

^a University of Louisville School of Medicine   (United States)

^b ILLINOIS STATE UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS   (United States)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^e OSF SAINT FRANCIS MEDICAL CENTER   (United States)

Author keywords

Bifidobacterium infantis 35624; irritable bowel syndrome; meta analysis; probiotic

Indexed keywords

PROBIOTIC AGENT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADVERSE DRUG REACTION; ARTICLE; BIFIDOBACTERIUM LONGUM SUBSP. INFANTIS; BLOATING; CLINICAL FEATURE; DEFECATION HABIT; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; GENERAL CONDITION IMPROVEMENT; HUMAN; IRRITABLE COLON; META ANALYSIS; NONHUMAN; SYSTEMATIC REVIEW; TREATMENT OUTCOME; FEMALE; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ABDOMINAL PAIN; BIFIDOBACTERIUM LONGUM SUBSPECIES INFANTIS; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 85014516752     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1080/03007995.2017.1292230     Document Type: Article

References (45)

1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE., AGA technical review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31
2. Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome:mechanisms and practical management. Gut 2007;56:1770-98
3. Sperber AD, Atzmon Y, Neumann L, et al. Fibromyalgia in the irritable bowel syndrome:studies of prevalence and clinical implications. Am J Gastroenterol 1999;94:3541-6
4. Gomborone JE, Gorard DA, Dewsnap PA, et al. Prevalence of irritable bowel syndrome in chronic fatigue. J Roy Coll Phys Lond 1996;30:512-13
5. Walker EA, Gelfand AN, Gelfand MD, et al. Chronic pelvic pain and gynecological symptoms in women with irritable bowel syndrome. J Psychosom Obstet Gynaecol 1996;17:39-46
6. Lydiard RB, Fossey MD, Marsh W, Ballenger JC., Prevalence of psychiatric disorders in patients with irritable bowel syndrome. Psychosomatics 1993;34:229-34
7. Camilleri M, Choi MG., Review article:irritable bowel syndrome. Aliment Pharmacol Therapeut 1997;11:3-15
8. Enck P, Junne F, Klosterhalfen S, et al. Therapy options in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2010;22:1402-11
9. Carroll IM, Ringel-Kulka T, Keku TO, et al. Molecular analysis of the luminal- and mucosal-associated intestinal microbiota in diarrhea-predominant irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2011;301:G799-807
10. Carroll IM, Ringel-Kulka T, Siddle JP, Ringel Y., Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome. Neuro Gastroenterol Motil 2012;24:521-30, e248
11. Lee BJ, Bak YT., Irritable bowel syndrome, gut microbiota and probiotics. Neuro Gastroenterol Motil 2011;17:252-66
12. Ringel Y, Maharshak N., Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2013;305:G529-41
13. Ringel-Kulka T, Choi CH, Temas D, et al. Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome. Am J Gastroenterol 2015;110:1339-46
14. O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome:symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51
15. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-90
16. Cappello C, Tremolaterra F, Pascariello A, et al. A randomised clinical trial (RCT) of a symbiotic mixture in patients with irritable bowel syndrome (IBS):effects on symptoms, colonic transit and quality of life. Int J Colorectal Dis 2013;28:349-58
17. Bucci C, Tremolaterra F, Gallotta S, et al. A pilot study on the effect of a symbiotic mixture in irritable bowel syndrome:an open-label, partially controlled, 6-month extension of a previously published trial. Tech Coloproctol 2014;18:345-53
18. Kim HJ, Vazquez Roque MI, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neuro Gastroenterol Motil 2005;17:687-96
19. Hu Y, Tao L, Lyu B., [A meta-analysis of probiotics for the treatment of irritable bowel syndrome]. Zhonghua nei ke za zhi 2015;54:445-51
20. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation:systematic review and meta-analysis. Am J Gastroenterol 2014;109:1547-61; quiz 1546, 1562
21. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome:a systematic review. Gut 2010;59:325-32
22. Ortiz-Lucas M, Tobias A, Saz P, Sebastian JJ., Effect of probiotic species on irritable bowel syndrome symptoms:a bring up to date meta-analysis. Revista Espanola de Enfermedades Digestivas 2013;105:19-36
23. Hoveyda N, Heneghan C, Mahtani KR, et al. A systematic review and meta-analysis:probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009;9:15
24. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS., The utility of probiotics in the treatment of irritable bowel syndrome:a systematic review. Am J Gastroenterol 2009;104:1033-49; quiz 1050
25. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials:is blinding necessary? Controlled Clinical Trials 1996;17:1-12
26. Senn S, Weir J, Hua TA, et al. Creating a suite of macros for meta-analysis in SAS:a case study in collaboration. Stat Probab Lett 2011;81:10
27. Higgins JP, Thompson SG., Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58
28. Charbonneau D, Gibb RD, Quigley EM., Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes 2013;4:201-11
29. Kelesidis T, Pothoulakis C., Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Ther Adv Gastroenterol 2012;5:111-25
30. Quigley EM., Probiotics in functional gastrointestinal disorders:what are the facts? Curr Opin Pharmacol 2008;8:704-8
31. Ringel-Kulka T, McRorie J, Ringel Y., Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the benefit of the probiotic Bifidobacterium infantis 35624 in non-patients with symptoms of abdominal discomfort and bloating. Am J Gastroenterol 2017;112:145-51
32. Kennedy PJ, Cryan JF, Quigley EM, et al. A sustained hypothalamic–pituitary–adrenal axis response to acute psychosocial stress in irritable bowel syndrome. Psychol Med 2014;44:3123-34
33. Allen AP, Hutch W, Borre YE, et al. Bifidobacterium longum 1714 as a translational psychobiotic:modulation of stress, electrophysiology and neurocognition in healthy volunteers. Translational Psychiatry 2016;6:e939
34. Barbara G, Cremon C, Carini G, et al. The immune system in irritable bowel syndrome. Neuro Gastroenterol Motil 2011;17:349-59
35. Camilleri M., Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2012;367:1626-35
36. Camilleri M, Lasch K, Zhou W., Irritable bowel syndrome:methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012;303:G775-85
37. Camilleri M., Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2013;368:578-9
38. Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011;364:22-32
39. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Therapeut 2003;17:895-904
40. Ferguson LR, Laing B, Marlow G, Bishop K., The role of vitamin D in reducing gastrointestinal disease risk and assessment of individual dietary intake needs:focus on genetic and genomic technologies. Mol Nutr Food Res 2016;60:119-33
41. Parkes GC, Rayment NB, Hudspith BN, et al. Distinct microbial populations exist in the mucosa-associated microbiota of sub-groups of irritable bowel syndrome. Neuro Gastroenterol Motil 2012;24:31-9
42. McCarthy J, O’Mahony L, O’Callaghan L, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003;52:975-80
43. Abbasnezhad A, Amani R, Hajiani E, et al. Effect of vitamin D on gastrointestinal symptoms and health-related quality of life in irritable bowel syndrome patients:a randomized double-blind clinical trial. Neuro Gastroenterol Motil 2016;28:1533-44
44. Hulisz D., The burden of illness of irritable bowel syndrome:current challenges and hope for the future. J Manag Care Pharm 2004;10:299-309
45. Guglielmetti S, Mora D, Gschwender M, Popp K., Randomised clinical trial:Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life–a double-blind, placebo-controlled study. Aliment Pharmacol Therapeut 2011;33:1123-32